These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 26930418)

  • 1. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
    Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
    Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
    Berntorp E; Negrier C; Gozzi P; Blaas PM; Lethagen S
    Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
    Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
    Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.
    Cheng X; Li P; Chen Z; Zhang N; Zhen Y; Zhao L; Wang X; Wu R
    Haemophilia; 2018 Jan; 24(1):120-125. PubMed ID: 29194866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
    Gringeri A; Wolfsegger M; Steinitz KN; Reininger AJ
    Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
    Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
    Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq
    Dargaud Y; Negrier C; Rusen L; Windyga J; Georgiev P; Bichler J; Solomon C; Knaub S; Lissitchkov T; Klamroth R
    Haemophilia; 2018 Jul; 24(4):619-627. PubMed ID: 29855112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.
    Saxena K; Lalezari S; Oldenburg J; Tseneklidou-Stoeter D; Beckmann H; Yoon M; Maas Enriquez M
    Haemophilia; 2016 Sep; 22(5):706-12. PubMed ID: 27339736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.
    Valentino LA; Mamonov V; Hellmann A; Quon DV; Chybicka A; Schroth P; Patrone L; Wong WY;
    J Thromb Haemost; 2012 Mar; 10(3):359-67. PubMed ID: 22212248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial.
    van Moort I; Preijers T; Bukkems LH; Hazendonk HCAM; van der Bom JG; Laros-van Gorkom BAP; Beckers EAM; Nieuwenhuizen L; van der Meer FJM; Ypma P; Coppens M; Fijnvandraat K; Schutgens REG; Meijer K; Leebeek FWG; Mathôt RAA; Cnossen MH;
    Lancet Haematol; 2021 Jul; 8(7):e492-e502. PubMed ID: 34171280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
    Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
    Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.
    Tarantino MD; Collins PW; Hay CR; Shapiro AD; Gruppo RA; Berntorp E; Bray GL; Tonetta SA; Schroth PC; Retzios AD; Rogy SS; Sensel MG; Ewenstein BM;
    Haemophilia; 2004 Sep; 10(5):428-37. PubMed ID: 15357767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A.
    Klamroth R; Simpson M; von Depka-Prondzinski M; Gill JC; Morfini M; Powell JS; Santagostino E; Davis J; Huth-Kühne A; Leissinger C; Neumeister P; Bensen-Kennedy D; Feussner A; Limsakun T; Zhou M; Veldman A; St Ledger K; Blackman N; Pabinger I
    Haemophilia; 2016 Sep; 22(5):730-8. PubMed ID: 27434619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A.
    Bonanad S; Núñez R; Poveda JL; Kurnik K; Goldmann G; Andreozzi V; Vandewalle B; Santos S
    Adv Ther; 2021 Sep; 38(9):4872-4884. PubMed ID: 34368918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
    Brand B; Gruppo R; Wynn TT; Griskevicius L; Lopez Fernandez MF; Chapman M; Dvorak T; Pavlova BG; Abbuehl BE
    Haemophilia; 2016 Jul; 22(4):e251-8. PubMed ID: 27328112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT
    Mingot-Castellano ME; Parra R; Núñez R; Martorell M
    Haemophilia; 2018 Sep; 24(5):e338-e343. PubMed ID: 30028549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose factor VIII infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor VIII consumption.
    Hua B; Lee A; Fan L; Li K; Zhang Y; Poon MC; Zhao Y
    Haemophilia; 2017 May; 23(3):417-421. PubMed ID: 28111886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.